Clinical Trial Update: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer [NA]

View source ↗

Summary

Clinical trial update indicates ongoing recruitment for Signatera-guided CDK4/6 inhibitor therapy in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor

Snippet

Sponsor: Natera, Inc. | Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast | NA | Status: RECRUITING